GlassScriptPhysician profile
Pedram Javanmard
NPI 1033475413
$5,689.33
in general payments reported to CMS, 2019-2025
43 companies · $1,144 in 2025
The $1,144 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $598 · 2022: $1,706 · 2023: $1,568 · 2024: $673 · 2025: $1,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $804.55 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $688.58 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $493.03 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $366.02 | 2021-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.18 | 2021-2025 | Jardiance |
| Corcept Therapeutics | $277.09 | 2021-2025 | Korlym |
| Abbott Laboratories | $251.78 | 2021-2023 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $239.29 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Beta Bionics, INC. | $167.45 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Medtronic, INC. | $162.15 | 2021-2025 | Minimed 780g, Intellis Adaptivestim |
| Amgen INC. | $150.14 | 2021-2025 | Evenity, Prolia, Tepezza |
| Radius Health, INC. | $148.55 | 2021-2025 | Tymlos |
| Insulet Corporation | $147.39 | 2021-2025 | Omnipod |
| Antares Pharma, INC. | $131.40 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Mannkind Corporation | $123.24 | 2022-2025 | Afrezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $119.98 | 2021-2023 | |
| Amryt Pharma Holdings LTD | $108.05 | 2022-2023 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $83.72 | 2022-2023 | Strensiq |
| Recordati_rare_diseases_inc. | $80.86 | 2022-2025 | Isturisa, Signifor Lar |
| Ascendis Pharma Endocrinology INC | $70.35 | 2023-2025 | Yorvipath |
| Nevro Corp. | $67.95 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $66.76 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $64.15 | 2021-2024 | Farxiga |
| Ultragenyx Pharmaceutical INC. | $55.91 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $44.13 | 2023-2024 | |
| Astellas Pharma US INC | $42.11 | 2024-2025 | Veozah |
| Dexcom, INC. | $41.30 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Abbvie INC. | $32.90 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $32.43 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $32.29 | 2025 | Rezdiffra |
| Neurocrine Biosciences, INC. | $32.29 | 2025 | |
| Becton, Dickinson and Company | $31.02 | 2022 | |
| Tolmar, INC. | $30.34 | 2023 | |
| Boston Scientific Corporation | $28.45 | 2023 | Varithena Administration Pack |
| Embecta Corp. | $27.29 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Halozyme INC | $24.94 | 2023 | |
| Amarin Pharma, INC. | $23.27 | 2022 | |
| Eusa Pharma (US) LLC | $20.92 | 2022 | |
| Horizon Therapeutics Plc | $20.77 | 2023 | Tepezza |
| Pfizer INC. | $18.10 | 2022 | |
| Ibsa Pharma INC. | $16.73 | 2022 | |
| Currax Pharmaceuticals LLC | $16.60 | 2021 | |
| Clarus Therapeutics INC. | $9.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Javanmard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.